EU completes Meridia review
Executive Summary
EU Committee for Proprietary Medicinal Products "issued a positive opinion reaffirming the favorable risk/benefit profile of sibutramine," Abbott announces June 27. The committee reviewed the obesity drug (Meridia in the U.S.) at the request of Italian Health Ministry after the agency suspended approval of sibutramine. Abbott expects FDA to respond by the fall to a petition from Public Citizen's Health Research Group asking that Meridia be withdrawn (1"The Pink Sheet" June 17, p. 16)...
You may also be interested in...
Meridia Growth Forecast Is 50% In 2002, Despite Italian Withdrawal – Abbott
Abbott's revised forecast for the anti-obesity agent Meridia (sibutramine) still assumes a 50% increase in worldwide sales for 2002
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.